SILEXION THERAPEUTICS CORP (SLXN)

Common Stock

2.44  +0.02 (+0.83%)

After market: 2.4 -0.04 (-1.64%)

SILEXION THERAPEUTICS CORP

NASDAQ:SLXN (12/20/2024, 8:00:02 PM)

After market: 2.4 -0.04 (-1.64%)

2.44

+0.02 (+0.83%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
GICS SubIndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-272.47%
Sales Q2Q%N/A
CRS0
6 MonthN/A
Overview
Earnings (Last)08-12 2024-08-12
Earnings (Next)N/A N/A
Ins OwnersN/A
Inst OwnersN/A
Market Cap9.44M
Shares3.87M
PEN/A
Fwd PEN/A
Dividend YieldN/A
AnalystsN/A
Short Float %N/A
Short Ratio0.01
IPO02-17 2021-02-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

SLXN Daily chart

Company Profile

Moringa Acquisition Corp. operates as a blank check company. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-17. The firm is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus its search on technology-based businesses that are domiciled in Israel, that carry out all or a substantial portion of their activities in Israel, or that have some other significant Israeli connection. The company has no operations and generates no revenues.

Company Info

SILEXION THERAPEUTICS CORP

250 Park Avenue, 7Th Floor

New York City NEW YORK

P: 12125726395

Employees: 0

Website: https://www.moringaac.com/

SLXN News

News Image6 days ago - PESG ResearchPESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
News Image13 days ago - Silexion Therapeutics CorpSilexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...

News Imagea month ago - Silexion Therapeutics CorpSilexion Therapeutics Announces 1-for-9 Reverse Share Split

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ...

News Imagea month ago - Silexion Therapeutics CorpSilexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA...

News Image3 months ago - AB NewswireSilexion Therapeutics Unveils Promising Preclinical Data for SIL-204 Just Days After New LODER Data: Advancing the Fight Against Pancreatic Cancer

SLXN Twits

Here you can normally see the latest stock twits on SLXN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example